#523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)
Banerjee S, Ring K, Niewenhuysen E, Fabbro M, Aghajanian C, Oaknin A, Colombo N, Santin A, Clamp A, Moore K, Rose P, David M O, Chon H, Salinas E, Prendergast E, Lustgarten S, Rodrigues M, Gennigens C, Monk B, Grisham R. #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC). 2023, a20-a21. DOI: 10.1136/ijgc-2023-esgo.29.Peer-Reviewed Original Research